Daxor Co. (NASDAQ:DXR – Get Free Report) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 14,900 shares, an increase of 144.3% from the November 15th total of 6,100 shares. Based on an average trading volume of 16,600 shares, the short-interest ratio is currently 0.9 days. Approximately 0.7% of the company’s stock are sold short.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC boosted its stake in Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.34% of the company’s stock.
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets lifted their target price on shares of Daxor from $24.50 to $24.75 and gave the stock a “buy” rating in a research report on Monday, September 9th.
Daxor Trading Down 2.9 %
Shares of DXR stock traded down $0.24 during mid-day trading on Friday, reaching $8.16. 9,171 shares of the company’s stock traded hands, compared to its average volume of 7,580. The firm has a 50 day moving average price of $9.05 and a two-hundred day moving average price of $8.98. Daxor has a 12 month low of $7.16 and a 12 month high of $10.04.
Daxor Company Profile
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Articles
- Five stocks we like better than Daxor
- Investing In Automotive Stocks
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Stock Sentiment Analysis: How it Works
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is the Australian Securities Exchange (ASX)
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.